시장보고서
상품코드
1937806

피브리노겐 농축물 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

Global Fibrinogen Concentrates Market Size, Share, Trends & Growth Analysis Report 2026-2034

발행일: | 리서치사: Value Market Research | 페이지 정보: 영문 138 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

피브리노겐 농축물 시장 규모는 2025년 43억 8,000만 달러에서 2034년에는 79억 1,000만 달러에 달할 것으로 예측되며, 2026년부터 2034년까지 CAGR 6.79%로 성장할 전망입니다.

피브리노겐 농축물 시장은 출혈성 질환의 유병률 증가와 수술 및 외상 치료에서 효과적인 지혈제에 대한 수요 증가로 인해 큰 폭의 성장이 예상됩니다. 피브리노겐은 응고 캐스케이드에서 중요한 단백질로 상처 치유와 혈전 형성에 매우 중요한 역할을 합니다. 의료진이 환자의 치료 결과를 개선하고 출혈 관련 합병증 위험을 줄이기 위해 피브리노겐 농축 제제의 사용이 점점 더 중요해지고 있습니다. 이 시장은 특히 대수술 환자나 선천성 피브리노겐 결핍 환자를 대상으로 지혈 효과를 높이기 위해 고안된 다양한 제품을 포괄하고 있습니다.

제조 공정 및 정제 기술 혁신을 통한 안전성 및 유효성 향상 등 기술적 진보가 피브리노겐 농축물 시장을 크게 형성하고 있습니다. 첨단 분획법 및 병원체 불활성화 기술의 개발로 피브리노겐 농축물의 품질이 향상되어 엄격한 규제 기준을 충족할 수 있습니다. 또한, 현장 검사 및 모니터링 시스템의 통합을 통해 의료진은 실시간으로 피브리노겐 농도를 평가할 수 있게 되어 적시에 개입하고 개별화된 치료 접근을 할 수 있게 되었습니다. 시장이 계속 진화하는 가운데, 혁신을 우선시하고 연구개발에 투자하는 기업이 경쟁 우위를 점할 가능성이 높을 것입니다.

또한, 피브리노겐 농축물 시장은 다양한 의료 응용 분야에서 피브리노겐의 사용을 촉진하는 규제 프레임워크와 임상 가이드라인의 영향을 점점 더 많이 받고 있습니다. 의료 시스템이 증거에 기반한 관행을 채택함에 따라 엄격한 임상시험을 통해 안전성과 유효성을 입증한 피브리노겐 농축물에 대한 수요는 계속 증가할 것입니다. 이러한 추세는 새로운 용도 발굴 및 기존 제형 개선을 위한 연구 이니셔티브에 대한 투자를 촉진하고 있습니다. 맞춤의료와 표적치료에 대한 관심이 높아짐에 따라 환자 개개인의 필요에 따라 조정 가능한 피브리노겐 농축 제제의 필요성이 확대될 것이며, 임상적 요구사항에 부합하는 제품을 제공하는 기업이 이 중요한 시장에서 성공할 수 있는 위치에 서게 될 것입니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 피브리노겐 농축물 시장 : 제품 유형별

제5장 세계의 피브리노겐 농축물 시장 : 용도별

제6장 세계의 피브리노겐 농축물 시장 : 최종사용자별

제7장 세계의 피브리노겐 농축물 시장 : 지역별

제8장 경쟁 구도

제9장 기업 개요

KSM 26.03.12

The Fibrinogen Concentrates Market size is expected to reach USD 7.91 Billion in 2034 from USD 4.38 Billion (2025) growing at a CAGR of 6.79% during 2026-2034.

The Fibrinogen Concentrates market is poised for significant growth, driven by the increasing prevalence of bleeding disorders and the rising demand for effective hemostatic agents in surgical and trauma settings. Fibrinogen, a critical protein in the coagulation cascade, plays a vital role in wound healing and blood clot formation. As healthcare providers seek to improve patient outcomes and reduce the risk of complications associated with bleeding, the use of fibrinogen concentrates is becoming increasingly important. This market encompasses a range of products designed to enhance hemostasis, particularly in patients undergoing major surgeries or those with congenital fibrinogen deficiencies.

Technological advancements are significantly shaping the Fibrinogen Concentrates market, with innovations in manufacturing processes and purification techniques enhancing product safety and efficacy. The development of advanced fractionation methods and pathogen inactivation technologies is improving the quality of fibrinogen concentrates, ensuring that they meet stringent regulatory standards. Additionally, the integration of point-of-care testing and monitoring systems is enabling healthcare providers to assess fibrinogen levels in real-time, facilitating timely interventions and personalized treatment approaches. As the market continues to evolve, companies that prioritize innovation and invest in research and development will likely gain a competitive edge.

Moreover, the Fibrinogen Concentrates market is increasingly influenced by regulatory frameworks and clinical guidelines that promote the use of fibrinogen in various medical applications. As healthcare systems adopt evidence-based practices, the demand for fibrinogen concentrates that demonstrate safety and efficacy through rigorous clinical trials will continue to rise. This trend is driving investment in research initiatives aimed at exploring novel applications and improving existing formulations. As the focus on personalized medicine and targeted therapies grows, the need for fibrinogen concentrates that can be tailored to individual patient needs will expand, positioning companies that align their offerings with clinical requirements for success in this vital market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

  • Human Fibrinogen Concentrate
  • Recombinant Fibrinogen Concentrate
  • Animal-Derived Fibrinogen Concentrate
  • Synthetic Fibrinogen Concentrate

By Application

  • Congenital Fibrinogen Deficiency
  • Surgical Procedures
  • Others

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

COMPANIES PROFILED

  • Baxter International Inc, Shanghai RAAS, Octapharma AG, Johnson and Johnson, ThermoFisher Scientific, ProFibrix BV, Enzo Life Sciences, Inc, CSL Behring, GC Biopharma, Hualan Biological Engineering Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL FIBRINOGEN CONCENTRATES MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product Type
  • 4.2. Human Fibrinogen Concentrate Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Recombinant Fibrinogen Concentrate Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Animal-Derived Fibrinogen Concentrate Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Synthetic Fibrinogen Concentrate Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL FIBRINOGEN CONCENTRATES MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Congenital Fibrinogen Deficiency Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Surgical Procedures Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL FIBRINOGEN CONCENTRATES MARKET: BY END USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End User
  • 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL FIBRINOGEN CONCENTRATES MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Product Type
    • 7.2.2 By Application
    • 7.2.3 By End User
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Product Type
    • 7.3.2 By Application
    • 7.3.3 By End User
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Product Type
    • 7.4.2 By Application
    • 7.4.3 By End User
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Product Type
    • 7.5.2 By Application
    • 7.5.3 By End User
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Product Type
    • 7.6.2 By Application
    • 7.6.3 By End User
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL FIBRINOGEN CONCENTRATES INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Baxter International Inc
    • 9.2.2 Shanghai RAAS
    • 9.2.3 Octapharma AG
    • 9.2.4 Johnson And Johnson
    • 9.2.5 ThermoFisher Scientific
    • 9.2.6 ProFibrix BV
    • 9.2.7 Enzo Life Sciences, Inc
    • 9.2.8 CSL Behring
    • 9.2.9 GC Biopharma
    • 9.2.10 Hualan Biological Engineering Inc
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제